UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers

Cancer, 2019-03, Vol.125 (5), p.698-703

2019

Volltextzugriff (PDF)

Neo‐adjuvant chemotherapy does not affect the immediate postoperative complication rate after breast reconstruction

The breast journal, 2019-05, Vol.25 (3), p.528-530

2019

Volltextzugriff (PDF)

Does nipple sparing mastectomy affect the postoperative complication rate after breast reconstruction? Comparison of postoperative complications after nipple sparing mastectomy vs skin sparing mastectomy

The breast journal, 2019-07, Vol.25 (4), p.755-756

2019

Volltextzugriff (PDF)

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

The New England journal of medicine, 2019-12, Vol.381 (25), p.2403-2415

2019

Volltextzugriff (PDF)

Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysis

The breast journal, 2020-10, Vol.26 (10), p.2096-2098

2020

Volltextzugriff (PDF)

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor

Journal of the National Comprehensive Cancer Network, 2015-09, Vol.13 (9), p.1061

2015

Volltextzugriff (PDF)

Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors

Familial cancer, 2021-07, Vol.20 (3), p.189-194

2021

Volltextzugriff (PDF)

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

Breast cancer research and treatment, 2020-05, Vol.181 (1), p.97-105

2020

Volltextzugriff (PDF)

Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2– Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial

Clinical breast cancer, 2018-04, Vol.18 (2), p.e197-e203

2018

Volltextzugriff (PDF)

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

NPJ breast cancer, 2023-09, Vol.9 (1), p.79-79, Article 79

2023

Volltextzugriff (PDF)

Association Between Standard Clinical and Pathologic Characteristics and the 21-Gene Recurrence Score in Breast Cancer Patients : A Population-based Study

Cancer, 2008-02, Vol.112 (4), p.731-736

2008

Volltextzugriff (PDF)

Association between standard clinical and pathologic characteristics and the 21‐gene recurrence score in breast cancer patients

Cancer, 2008-02, Vol.112 (4), p.731-736

2008

Volltextzugriff (PDF)

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Obstetrical & gynecological survey, 2017-02, Vol.72 (2), p.91-92

2017

Volltextzugriff (PDF)

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

The New England journal of medicine, 2016-12, Vol.375 (22), p.2154-2164

2016

Volltextzugriff (PDF)

Advanced Breast Cancer at Diagnosis: Over One Third Adherent to Screening Recommendations

Women's health reports (New Rochelle, N.Y.), 2020-01, Vol.1 (1), p.301-307

2020

Volltextzugriff (PDF)

Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer

Onkologie, 2012-01, Vol.35 (7-8), p.427-431

2012

Volltextzugriff (PDF)

Pretreatment CA 15-3 Levels do not Predict Disease-Free Survival in Patients with Advanced Epithelial Ovarian Cancer

Tumori, 2013-03, Vol.99 (2), p.257-260

2013

Volltextzugriff (PDF)

Malignant ascites and bacterial peritonitis

Medical journal of Australia, 2006-01, Vol.184 (2), p.92-93

2006

Volltextzugriff (PDF)

D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (23), p.6856-6864

2013

Volltextzugriff (PDF)

Phase II Study of UFT with Leucovorin Plus Hepatic Arterial Infusion with Irinotecan, 5-Fluorouracil and Leucovorin for Non-Resectable Liver Metastases of Colorectal Cancer

Chemotherapy (Basel), 2009-01, Vol.55 (2), p.76-82

2009

Volltextzugriff (PDF)

An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (∗)

The Journal of biological chemistry, 1996-03, Vol.271 (13), p.7620-7629

1996

Volltextzugriff (PDF)

The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC

Clinical breast cancer, 2022-04, Vol.22 (3), p.223-234

2022

Volltextzugriff (PDF)

Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer

Acta oncologica, 2007, Vol.46 (3), p.324-329

2007

Volltextzugriff (PDF)

Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.565-565

2022

Volltextzugriff (PDF)

Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-08-14

2022

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(63)
Berichte
(1)

Sprache

Englisch
(64)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(40)
Science & Technology
(40)
Humans
(35)
Oncology
(29)
Female
(27)
Middle Aged
(22)
Breast Cancer
(20)
Adult
(19)
Aged
(16)
Breast Neoplasms - Pathology
(12)
Chemotherapy
(12)
Biological And Medical Sciences
(11)
Medical Sciences
(10)
Tumors
(9)
Cancer Therapies
(8)
Male
(8)
Aged, 80 And Over
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Cancer
(7)
Gynecology. Andrology. Obstetrics
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers

Neo‐adjuvant chemotherapy does not affect the immediate postoperative complication rate after breast reconstruction

Does nipple sparing mastectomy affect the postoperative complication rate after breast reconstruction? Comparison of postoperative complications after nipple sparing mastectomy vs skin sparing mastectomy

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysis

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor

Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2– Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Association Between Standard Clinical and Pathologic Characteristics and the 21-Gene Recurrence Score in Breast Cancer Patients : A Population-based Study

Association between standard clinical and pathologic characteristics and the 21‐gene recurrence score in breast cancer patients

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Advanced Breast Cancer at Diagnosis: Over One Third Adherent to Screening Recommendations

Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer

Pretreatment CA 15-3 Levels do not Predict Disease-Free Survival in Patients with Advanced Epithelial Ovarian Cancer

Malignant ascites and bacterial peritonitis

D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

Phase II Study of UFT with Leucovorin Plus Hepatic Arterial Infusion with Irinotecan, 5-Fluorouracil and Leucovorin for Non-Resectable Liver Metastases of Colorectal Cancer

An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (∗)

The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC

Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer

Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry

Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry

Suchergebnisse filtern